Beruflich Dokumente
Kultur Dokumente
en fibrilación
auricular
Sergio Nicolás Giraldo G.
XII semestre Medicina
Universidad Nacional de Colombia
Definición
La fibrilación auricular es la arritmia cardiaca (supraventricular) mas
frecuente en humanos.
Activación eléctrica desordenada de las aurículas, ya sea por actividad
propia u originada en las venas pulmonares.
R-R irregular
• Predisposición genética
FA de inicio temprano. Miocardiopatías o canalopatías mediadas por
mutaciones.
Acortamiento periodo refractario de los miocitos auriculares.
FA valvular FA no valvular
“Estenosis mitral severa a Escalas de riesgo:
moderada y/o válvula cardiaca CHA2-DS2-VASc >2 en H
mecánica” CHA2-DS2-VASc >3 en M
Warfarina Warfarina
O
NOACs
2016 ESC Guidelines for the Management of Atrial Fibrillation
Prevención ACV
Warfarina NOACs
Primeros anticoagulantes Aumento en la practica clínica
empleados en FA Efecto predecible
Reduce 60% riesgo de ACV y 25% No requieren monitorización
mortalidad comparado con ASA o regular
placebo.
Requiere: Intervalo terapéutico
IIa Xa
• Dabigatran • RivaroXaban
• ApiXaban
RE-LY • EdoXaban
NEJM (2009). Dabigatran versus Warfarin in Patiens with Atrial Fibrillation.
NEJM (2009). Dabigatran versus Warfarin in Patiens with Atrial Fibrillation.
Lancet (2014). Comparision of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Metanalisis: ACV y embolia pulmonar
Lancet (2014). Comparision of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Metanalisis: Desenlaces en seguridad y eficacia
Lancet (2014). Comparision of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Recomendaciones
AHA 2019
• Se recomiendan los NOACs sobre el uso de Warfarina en pacientes
con FA no valvular. Tratamiento de primera línea.
Nivel de evidencia A, grado de recomendación I.
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation
Recomendaciones
AHA 2019
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Referencias
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr,
Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray
KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS focused
update of the 2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines and the Heart Rhythm Society. Circulation.
Gracias!
2019;139
2016 ESC Guidelines for the Management of Atrial Fibrillation
Developed in Collaboration With EACTS
Lancet (2014). Comparision of the efficacy and safety of new oral
anticoagulants with warfarin in patients with atrial fibrillation: a
meta-analysis of randomised trials
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS
guideline for the management of patients with atrial fibrillation
2014 AHA/ACC/HRS Guideline for the Management of Patients With
Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines and the Heart Rhythm Society